Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
about
Antibiotics for community-acquired pneumonia in adult outpatientsSafety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase.The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers.Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavageCombating multidrug-resistant Gram-negative bacterial infections.The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.Reducing antibacterial development risk for GSK1322322 by exploring potential human dose regimens in nonclinical efficacy studies using immunocompetent rats.Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.In vitro and intracellular activities of peptide deformylase inhibitor GSK1322322 against Legionella pneumophila isolatesLigand and Structure-Based Approaches for the Identification of Peptide Deformylase Inhibitors as Antibacterial Drugs.Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor.
P2860
Q24193127-EFA98D8B-E53B-4133-8021-90C7D310EC47Q34596497-EBEAB2E0-6B71-4710-8AF0-1DCC69418454Q35105814-598D75A1-B5EF-4845-AFB6-E64679FC0517Q35742017-01B7CA99-7A43-4406-A4E5-5D65CFBD37DDQ37544388-26830C94-EA4D-4EF6-938B-4536CBEE1B34Q37544570-BEEAF922-231B-4686-B7CE-AA207393CAB6Q38161570-603569E7-16B0-46D9-8250-7E2AAC773437Q38633668-8D039A6F-AB0D-4836-B1C7-1D02A2ADD380Q40093553-D834F261-E442-4E9D-8963-AC2DE9C3E1B3Q40414549-76A3A6BE-3099-49FB-B952-B819461B3005Q41200948-2954BC3C-80BF-4BE8-A40A-D5C7564EC0E1Q41687404-91C62CCB-286C-41E9-B09E-81E65F6E44EAQ42397239-4BB90A0D-ABA4-4B87-A792-FFC47643950AQ44621130-D9054FF6-4AA6-4D41-9F86-AA5F16720499
P2860
Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Single-dose safety, tolerabili ...... peptide deformylase inhibitor.
@en
type
label
Single-dose safety, tolerabili ...... peptide deformylase inhibitor.
@en
prefLabel
Single-dose safety, tolerabili ...... peptide deformylase inhibitor.
@en
P2093
P2860
P356
P1476
Single-dose safety, tolerabili ...... peptide deformylase inhibitor.
@en
P2093
Etienne Dumont
Lori S Jones
Milena Kurtinecz
Odin J Naderer
P2860
P304
P356
10.1128/AAC.01779-12
P407
P577
2013-02-12T00:00:00Z